Beyond Blood Sugar: How Type 1 Diabetes Care Is Evolving

Fifty years ago, a Type 1 diabetes diagnosis often meant a shortened lifespan. Today, insulin therapy, continuous glucose monitors, and hybrid closed-loop systems have transformed the picture. People with Type 1 can now live full, long lives.

But as survival has improved, researchers have noticed something important: achieving near-normal blood sugar levels hasn't eliminated all the extra health risks that come with Type 1 diabetes. People still face higher rates of heart disease, infections, and cognitive decline compared to those without diabetes. This suggests that past episodes of high and unstable blood sugar leave a lasting imprint on the body—even after modern tools bring levels under control.

For decades, the main goal of Type 1 diabetes treatment has been lowering HbA1c—a measure of average blood sugar over three months. Logically, it made sense: lower numbers should mean fewer complications.

New evidence is challenging this assumption. At the population level, pushing blood sugar numbers lower isn't reliably producing the health improvements doctors expected. This doesn't mean blood sugar control is unimportant, but it does suggest that focusing on one number alone may miss other pieces of the puzzle.

Researchers are now proposing a broader definition of successful Type 1 diabetes treatment: physiological resilience. This means helping the body regulate itself more naturally, keeping blood sugar stable rather than bouncing around, and reducing the chronic inflammation that Type 1 diabetes creates.

Under this framework, the goal isn't just a low HbA1c—it's a metabolic state that resembles how the body works without diabetes. That could mean less daily burden from checking blood sugar, taking insulin, and managing the constant demands of the disease.

Therapies that replace or restore insulin-producing cells—including pancreas transplants, islet transplants, and emerging stem cell-derived implants—are being reconsidered through this new lens. Rather than judging success solely on blood sugar numbers, researchers suggest these treatments should be measured on:

Whether they preserve the body's own insulin-producing capacity (C-peptide levels), how stable blood sugar remains, how long the benefit lasts, safety, and how patients actually feel and function in daily life.

This shift reflects a fundamental truth: the best treatment is one that works durably, keeps blood sugar in a stable range, and reduces the daily burden of managing Type 1 diabetes.

Source: The lancet. Diabetes & endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.